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ABSTRACT Loss of cholinergic transmission in the cortex and hippocampus is a
characteristic feature of Alzheimer’s disease, and visualization of functional cholinergic
synapses in the brain with PET could be a useful method for studying this degenerative
condition in living humans. We investigated [18F]fluoroethoxybenzovesamicol, (2)-
[18F]FEOBV, (2)-(2R,3R)-trans-2-hydroxy-3-(4-phenylpiperidino)-5-(2-[ 18F]fluoroethoxy)-
1,2,3,4-tetralin, a high affinity positron emitting ligand for the vesicular acetylcholine
transporter, as a potential in vivo cholinergic synapse mapping agent. Rodent biodistribu-
tion, dosimetry, stereospecificity of biological effects, pharmacologic blocking studies, in
vivo rodent brain autoradiography and metabolites were examined. (2)-[18F]FEOBV
brain uptake following intravenous injection was robust, with 2.65% dose/brain in mice
at 5 min, and the regional localization matched the known distributions of presynaptic
cholinergic markers at later times. Both the cholinergic localization and curare-like
effects of FEOBV were associated with the ‘‘(2)’’-enantiomer exclusively. (2)-
[18F]FEOBV regional brain distribution in rodents was changed little by pretreatment
with haloperidol, (1)-3-PPP, or E-2020, indicating FEOBV, unlike other vesamicol
analogs, did not interact in vivo with dopamine or s receptor systems. Autoradiography of
rat brain 3 h following i.v. injection of (2)-[18F]FEOBV showed high localization in brain
areas rich in presynaptic cholinergic elements. Metabolic defluorination in rodents was
modest, and analysis of brain tissue following tracer administration found FEOBV as the
only extractable radioactive species. (2)-[18F]FEOBV dosimetry calculated from rat data
estimate 10 mCi doses can be given to humans. These studies show FEOBV maps
cholinergic areas with high specificity in vivo, and may provide a noninvasive means to
safely and accurately gauge the functional integrity of cholinergic synapses in man using
PET. Synapse 30:263–274, 1998. r 1998 Wiley-Liss, Inc.
INTRODUCTION
A dramatic loss of acetylcholine (ACh) and its meta-
bolically related enzymes from the cortex and hippocam-
pus is a characteristic feature of Alzheimer’s disease
(AD) (Perry et al., 1994). In addition, loss of synaptic
elements in the cortex and subcortical brain areas is
correlated with the severity of cognitive decline in AD
(Davies et al., 1987; DeKosky and Scheff, 1990; Masliah
et al., 1992a,b; Samuel et al., 1994; Scheff et al., 1990;
Terry et al., 1991). Some studies have found synaptic
and neuronal loss to be even more strongly correlated
with AD symptoms than the senile plaques and neurofi-
brillary tangles that are the diagnostic hallmarks of the
disease (Gomez-Isla et al., 1997; Masliah et al., 1992b;
Svennerholm and Gottfries, 1994; Terry et al., 1991).
The synaptic pathology of AD involves neurons of
multiple transmitter types, but loss of cholinergic pre-
synaptic function in the neocortex appears to be a
crucial component in the development of visuospatial
deficits and impaired working memory that occurs with
the disease (Perry et al., 1994). Several current pharma-
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cologic treatments for AD are aimed at enhancing
cholinergic neurotransmission in the brain (Brennan,
1997). The root causes of neurodegeneration in AD are
not understood (Itzhaki, 1994), and a definitive diagno-
sis of disease can be made only after death. The ability
to measure cholinergic synapses in the living human
brain could be an important investigative tool for
assessing neuronal damage, or for monitoring the effi-
cacy of future neuron-sparing therapies for this devas-
tating condition.
For these reasons, considerable efforts have been
focused on developing radiotracer imaging techniques
to visualize elements of presynaptic cholinergic func-
tion. One approach has employed radiolabeled ligands
or substrates of acetylcholinesterase (AChE) as mark-
ers of cholinergic activity (Irie et al., 1994; Kilbourn et
al., 1996; Pappata et al., 1996). Another method, and
the basis for the present work, targets the vesicular
ACh transporter (VAChT) in cholinergic terminals with
radiolabeled forms of the drug vesamicol (Altar and
Marien, 1988). VAChT is a glycoprotein located in
cholinergic synaptic vesicle membranes which draws
cytoplasmic ACh into the vesicles. Vesamicol binds on
VAChT to a so-called vesamicol receptor site that is
noncompetitive with ACh binding and, therefore, pre-
sumably not affected by changes in endogenous ACh
levels. VAChT tissue distribution is highly correlated
and uniquely distributed with other proteins involved
in the presynaptic metabolism of ACh, including cho-
line acetyltransferase (ChAT), high affinity choline
uptake protein, and acetylcholinesterase. The close
association of VAChT with other cholinergic markers
was recognized originally from vesamicol binding stud-
ies (Altar and Marien, 1988), and has been confirmed
recently using hybridization binding techniques with
cloned VAChT gene cDNA probes (Erickson et al., 1994,
1996; Roghani et al., 1994), and VAChT immunochemis-
try (Gilmor et al., 1996). It has been discovered that the
human VAChT gene lies nestled within the ChAT gene
locus and these two genes are co-expressed in a tightly
coupled fashion. A mounting body of evidence points to
VAChT as being a very specific marker of cholinergic
terminals. General recognition of this fact, and the
discovery of many potent analogs based on the vesami-
col template, has spurred the search for suitable radio-
ligands for measuring VAChT in vivo (Efange et al.,
1992; Parsons and Rogers, 1993; Efange et al., 1993,
1994, 1995a; Jung et al., 1996; Mach et al., 1997).
We studied a class of analogs called benzovesamicols,
discovered by Rogers et al. (1989), and identified a
number of novel radiolabeled benzovesamicol analogs
which distribute in vivo in patterns that correlate
closely with the densities of marker proteins of the
cholinergic nerve terminal. Analogs with radioiodine,
carbon-11, or fluorine-18 labels at the 5 position of the
2-hydroxy-3-N-(4-phenyl)-piperidino-tetralin frame-
work, which we term 5-substituted-benzovesamicols
(other investigators identify the same compounds as
4-benzovesamicols using a different nomenclature; see
Parsons and Rogers, 1993) have shown particularly
favorable imaging properties (Jung et al., 1990; Kil-
bourn et al., 1990; Mulholland et al., 1991a,b; Ingvar et
al., 1993). Human SPECT (single photon emission
computed tomography) imaging studies with the 123I-
labeled benzovesamicol analog 5-IBVM show decreases
in tracer binding in several brain regions of AD patients
(Kuhl et al., 1994, 1996). These studies offer encourage-
ment that appropriate benzovesamicol tracers can map
cholinergic neurons and gauge the functional integrity
of cholinergic synapses in man.
With the aim to extend human benzovesamicol imag-
ing studies to a higher level of precision with positron
emission tomography (PET), we developed a novel
fluorine-18-labeled agent, 5-fluoroethoxy-benzovesami-
col (FEOBV, Fig. 1). The synthesis of [18F]FEOBV
(Mulholland et al., 1993) and an examination of its
kinetics in the perfused rat heart (Degrado et al., 1994)
were reported previously. The present communication
examines distribution and pharmacologic properties of
FEOBV in animals, compares them with those of
related agents, and covers evaluation steps of FEOBV
preliminary to its introduction as an investigational
cholinergic synaptic tracer for human PET imaging
studies.
MATERIALS AND METHODS
(2)-[18F]FEOBV was labeled in a ‘‘one-step’’ nucleo-
philic radiofluorination procedure from ‘‘no-carrier-
added’’ [18F]fluoride ion and (2)-(2R,3R)-5-(2-tosyloxy-
ethoxy)-benzovesamicol (Mulholland et al., 1993). The
specific activity of the final tracer product at the end of
synthesis exceeded 3 Ci/µmol (range 3–17 Ci/µmol,
average 8 Ci/µmol) following HPLC purification, and
the radiochemical purity was greater than 99%, as
assayed by reverse phase HPLC. The inactive ‘‘(1)’’-
enantiomer of FEOBV was labeled by the same route to
the same quality specifications as (2)-FEOBV, starting
from resolved (1)-5-(2-tosyloxyethoxy)-benzovesami-
col.
Experiments with living animals were performed in
accordance with the United States Department of Agri-
culture Animal Welfare Act.
Mouse biodistribution studies
Female CD-1 mice weighing 23–34 g were anesthe-
tized lightly with diethyl ether and given tail vein
injections of 7–600 µCi of (2)-[18F]FEOBV. The animals
then resumed normal activity until the times of sacri-
fice, which ranged from 5 min to 15 h postinjection.
Mice were killed under ether anesthesia by decapita-
tion and tissues were quickly excised, weighed, and
counted for radioactivity in an auto gamma counter.
Samples from brains included striatum, whole cerebral
cortex, hippocampus, hypothalamus, and cerebellum.
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The results were corrected for radioactive decay and
expressed in terms of percent injected dose per organ
(%dose/organ), percent injected dose per gram of tissue
(%dose/g), normalized to an animal weight of 25 g.
Tissue concentration ratios were calculated from tissue
pairs for each animal and then averaged together to
yield tissue-to-cerebellum ratios. Each data point repre-
sented the mean 6 standard deviation of values from at
least three animals. Data were analyzed for signifi-
cance using unpaired two-tailed t-tests.
Pharmacologic pretreatment studies
Female CD1 mice (n 5 3 per data point) were given
interperitoneal injections of either haloperidol (10 mg/
kg), (1)-3-PPP (20 mg/kg), or E-2020 (donepezil) (10
mg/kg) 30 to 60 min prior to FEOBV radiotracer
administration (30 µCi, ,4 pmol FEOBV). Groups of
mice were sacrificed at 5, 45, and 240 min posttracer
and brain regions were dissected and counted for
radioactivity.
Rat biodistribution for dosimetry
Male and female Sprague Dawley (SD) rats weighing
215–275 g were injected with 50–120 µCi of (2)-
[18F]FEOBV via femoral vein while anesthetized with
ether, and then allowed to recover and resume normal
activity. Groups of animals were sacrificed by decapita-
tion at 5, 15, 30, and 120 min following injection, and
tissues and fluids were excised and counted for radioac-
tivity in an auto-gamma counter. The radioactivity
remaining in the carcass after removal of samples was
measured in a dose calibrator. Values were corrected for
decay and calculated as described above for mouse
experiments. Each data point in the rat biodistribution
data represents the mean 6 standard deviation of at
least four animal values, except for sex organs, for
which n 5 2–3. Dosimetry data were calculated using
the rat biodistribution data, following the MIRD formal-
ism (Loevinger and Berman, 1976). The percent admin-
istered dose per organ values were modified to reflect
the different proportions of organ to total body mass in
rat and man (Roedler, 1980). Residence times were
obtained by integration under the organ time vs. activ-
ity curves, with the effective halflife of (2)-[18F]FEOBV
assumed to be equal to the physical halflife of 18F for
times exceeding the last data point. Residence times
were entered into the MIRDOSE2 program (Watson et
al., 1988) for the generation of absorbed doses to
selected target organs per unit of administered activity.
Rodent brain and blood metabolite assays
Groups of three female CD-1 mice (24–30 g), under
ether anesthesia, were injected intravenously with ,1
mCi of [18F]FEOBV. They were allowed to recover and
resume normal activity until time of sacrifice at 30 and
90 min following tracer injection. The whole brains of
the three animals were removed, pooled together, and
homogenized in an equal volume of pH 7.6 TRIS/salt
buffer (120 mM NaCl, 50 mM TRIS, 5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2). The supernatant extract was
separated from sediment by low-speed centrifugation
and collected. The sediment was then shaken with a 3
mL portion of ethanol, recentrifuged, and the extract
combined with the first. This step was repeated. The
combined extracts, which contained more than 97% of
the original brain radioactivity, were concentrated to
near dryness under reduced pressure, then CH3CN (6
mL) was added and the resulting heterogeneous mix-
ture was concentrated to a volume of 1 mL. The solution
was decanted from the precipitated fatty solids, and the
fats were rinsed once with 1 mL of fresh CH3CN. The
combined final CH3CN solution (overall recovery 59%
from brain) was assayed by thin layer chromatography
(Analtech silica, 2:1:1:0.2 hexane: CH2Cl2: Et2O: Et3N;
Bioscan TLC plate reader; RfFEOBV 5 0.75) and HPLC
(column: 5 micron C-18 silica, mobile phase: 1.5 mL/
min, 3:1:1 CH3CN: MeOH: 20 mM KHPO4, pH 6.7,
serial UV (220 nm) and g radioactivity (CaF2) flow
detectors; k8FEOBV 5 3.25).
The brain radioactivity from two female rats was
examined separately in the same way 30 min following
2.3 and 4.3 mCi (femoral vein) injections of FEOBV. The
overall recovery in these cases were 70% and 66%.
Two anesthetized female rats were injected in the tail
vein with 6 and 8 mCi of (2)-[18F]FEOBV, respectively.
Blood samples (0.1–0.3 mL) were withdrawn from a
catheter in the vena cava at 5, 10, 30, and 60 min
postinjection, diluted with 1 mL of isotonic saline, and
centrifuged. In each sample the plasma was collected
and 1 mL of 70% ethanol was added to the cells; the
tube was vibramixed briefly, centrifuged again, and the
supernatant collected and combined with the plasma.
The combined extract and residual solids from each
blood sample were counted separately, and in cases
where the extract recovery was less than 80%, the
solids were subjected to a second extraction procedure
in which they were washed twice with 1 mL portions of
10% trifluoroacetic acid in methanol. All extracts were
concentrated, made basic with triethylamine, and ana-
lyzed by TLC.
In vivo rat brain autoradiography
Two restrained conscious female SD rats were in-
jected intravenously with (2)-[18F]FEOBV (4–9 mCi/
rat), and then 5 min and 3 h later they were sacrificed
by intravenous pentobarbital, followed by KCl injec-
tion. Brains were quickly excised, frozen in powdered
CO2 ice, coated with frozen section imbedding medium
(Lipshaw, Detroit, MI) and sectioned at 215°C into
20-µm thick slices. Brain slices were air-dried at 85°C
on polylysine-treated slides and were exposed to LKB
Betamax Ultrafilm for 12 h before development in
Kodak D-19. Autoradiograms were analyzed by com-
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puter assisted densitometry (MCID System, Imaging
Research, St Catherines, ONT). Brain regions identi-
fied included areas with anticipated high and low levels
of cholinergic markers on the basis of prior rodent and
primate studies, and included the interpeduncular
nucleus, basolateral amygdala, striatum, dentate gy-
rus, CA1 and CA3 fields of the hippocampus, frontal
cortex, occipital cortex, superficial layers of the superior
colliculus, thalamus, and cerebellar cortex.
RESULTS
Rodent brain uptake
(2)-[18F]FEOBV was rapidly taken up by the brain
following intravenous injection. There was 2.68 6
0.62% of the injected dose present in the whole brain of
mice at 5 min, and nearly 1.5% remained in the brain at
6 h. In rats the peak brain content was 1.58 6 0.20% of
the administered dose at 15 min. Mouse brain concen-
trations of (2)-[18F]FEOBV radioactivity were exam-
ined at 5, 10, and 45 min, and 3, 4, 6, and 15 h follow-
ing tracer administration. Time activity curves of
[18F]FEOBV in selected brain regions are shown in
Figure 2a. Tracer levels peaked within the first 5 min in
all brain regions except striatum. Peak striatal accumu-
lation in mice occurred between 45 and 180 min.
Clearance was slowest from striatum, fastest from
cerebellum, and intermediate from other brain areas.
Figure 2b shows tissue [18F]FEOBV localization in mice
expressed as a ratio relative to cerebellar concentra-
tions. The regional brain localization ratio in mice at
15 h postinjection, the latest time point examined, was
41:10:12:1 striatum: cortex: hippocampus: cerebellum,
respectively. [18F]FEOBV mouse brain uptake and local-
ization was very similar to that of the closely related
analogs [123/125I]IBVM (Jung et al., 1990) and [11C]MABV
(Kilbourn et al., 1990).
In vivo rat brain autoradiography
Rats sacrificed 5 min after tracer administration had
fairly uniform (2)-[18F]FEOBV radioactivity levels
throughout the brain, but (2)-[18F]FEOBV was distrib-
uted heterogenously in animals sacrificed at 3 h, with
high localizations in certain tissue areas. Highest radio-
activity densities appeared in interpeduncular nucleus,
followed by basolateral amygdala, striatum, dentate
gyrus, CA1 field of the hippocampus, CA3 field of the
hippocampus, frontal cortex, occipital cortex, superfi-
cial layers of the superior colliculus, thalamus, and
cerebellar cortex. This rank order is consistent with the
levels of ChAT (Fuhrmann et al., 1985; Tucek, 1988)
and high affinity choline transport-hemicholinium-3
binding (Bekenstein and Wooten, 1989; Happe and
Murrin, 1993; Vickroy et al., 1984).
Fig. 2. (2)-FEOBV regional brain time activity curves (A), and
tissue-to-cerebellum ratios (B), in the mouse. Values represent mean
6SEM of at least three animals.
Fig. 1. Structures of 5-substituted benzo-
vesamicol imaging agents IBVM, MABV, and
FEOBV.
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In vivo cholinergic specificity and lack
of interaction with dopamine neurons
or sigma sites
The tissue-to-cerebellum ratios of (2)-[18F]FEOBV in
various brain regions of the mouse at 6 and 15 h
postinjection showed close correspondence to the re-
ported levels of ChAT and AChE and [3H]hemicholin-
ium-3 binding in the same regions in rodents (Table I).
To investigate possible binding interactions of (2)-
[18F]FEOBV with dopamine D2 or s receptors, we
examined the effects of large pretreatment doses of the
potent D2 and s ligand haloperidol, the s ligand (1)-3-
PPP (3-(3-hydroxyphenyl)-N-propylpiperidine, Koe et
al., 1989), or E-2020 (donepezil, AriceptTR; a s ligand
and AChE inhibitor, Brennan, 1997; Koe et al., 1991),
on mouse brain distribution of the tracer. None of the
pretreatments produced changes in the tissue/cerebel-
lum ratios that were significantly different (P , 0.05)
from 5, 45, or 240 min control values (Table II).
Haloperidol pretreatment reduced the total (2)-[18F]FE-
OBV brain uptake by 20–30%, and blood activity by
25–50% at 5 min and 45 min following tracer adminis-
tration. By 240 min, total brain uptake and blood
activity in the haloperidol group was the same as for
controls, and striatal uptake of (2)-[18F]FEOBV was
elevated 36% relative to controls. No significant differ-
ences from control data were seen in the (1)-PPP and
E2020 groups’ total brain uptake, regional brain up-
take, or blood levels.
We examined the stereospecificity of [18F]FEOBV
tissue uptake by labeling the (1)dextrorotatory enanti-
omer, (1)-[18F]FEOBV and comparing its biodistribu-
tion in the mouse with (2)-[18F]FEOBV at 5, 45, and
180 min. Both isomers showed fairly homogeneous















Striatum 9.96 6 4.21 41.3 6 19.5 57.4 6 5.26 23.2 6 1.31 165 6 9.3
Cortex 4.70 6 1.82 10.3 6 5.55 13.9 6 1.50 4.12 6 0.27 23.5 6 3.8
Hippocampus 3.91 6 1.51 12.2 6 7.03 20.3 6 0.88 5.52 6 0.23 46.5 6 4.3
Hypothalamus 2.16 6 0.71 1.85 6 0.64 9.14 6 0.86 4.67 6 0.86 n.a.
Cerebellum 1 1 1.09 6 0.11 n.a. 4.8 6 0.8
*Data from Fuhrmann, 1985.
**Data from Vickroy, 1984.














5 min 2.68 6 0.62 1.93 6 0.18 (p 0.09) 2.45 6 0.70 2.90 6 0.18
45 min 2.14 6 0.11 1.55 6 0.06*** 2.13 6 0.15 1.93 6 0.20
240 min 1.55 6 0.30 1.50 6 0.11 1.49 6 0.20 1.42 6 0.12
%dose/g tissue
Striatum
5 min 6.02 6 0.75 4.77 6 0.70 (p 0.06) 6.21 6 0.55 6.14 6 1.0
45 min 8.09 6 1.06 8.67 6 0.90 8.52 6 1.12 7.63 6 0.49
240 min 7.29 6 0.94 9.88 6 0.54** 7.50 6 0.74 6.71 6 0.25
Cortex
5 min 5.00 6 1.76 4.56 6 0.22 5.92 6 0.45 5.82 6 0.52
45 min 4.65 6 0.68 4.11 6 0.07 4.30 6 0.22 4.10 6 0.29
240 min 3.30 6 0.56 3.46 6 0.40 3.20 6 0.17 2.85 6 0.05
Hippocampus
5 min 5.12 6 0.30 3.94 6 0.54** 4.94 6 0.56 5.19 6 0.28
45 min 4.40 6 0.58 3.92 6 0.08 4.04 6 0.18 3.73 6 0.41
240 min 2.91 6 0.46 3.22 6 0.15 2.94 6 0.17 2.70 6 0.30
Cerebellum
5 min 4.40 6 0.26 3.30 6 0.28** 4.28 6 0.28 4.52 6 0.25
45 min 2.34 6 0.24 2.15 6 0.06 2.48 6 0.04 2.33 6 0.10
240 min 1.19 6 0.37 1.37 6 0.10 1.46 6 0.21 1.41 6 0.01
Blood
5 min 2.11 6 0.28 1.46 6 0.21* 2.03 6 0.13 1.97 6 0.17
45 min 2.96 6 0.33 1.65 6 0.06*** 3.16 6 0.14 2.97 6 0.17
240 min 1.42 6 0.59 1.62 6 0.09 1.94 6 0.09 1.89 6 0.06
Tissue/cerebellum ratios
Striatum
45 min 3.46 6 0.39 4.04 6 0.52 3.45 6 0.47 3.02 6 0.40
240 min 6.50 6 1.55 7.26 6 0.80 5.17 6 0.68 4.76 6 0.13
Cortex
45 min 1.99 6 0.30 1.91 6 0.05 1.72 6 0.10 1.63 6 0.26
240 min 2.99 6 0.87 2.50 6 0.30 2.23 6 0.30 2.00 6 0.04
*P , .05, **P , .005, ***P , .0005, different from controls by two-tailed t-test. Percent injected dose per gram of tissue, normalized to a 25 g mouse.
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brain uptakes of similar magnitude at 5 min, but at
later times the (1)-isomer brain distribution stayed
uniform and comparable to the cerebellar level of
(2)-[18F]FEOBV, whereas the ‘‘cholinergic’’ pattern of
brain localization was specific to the (2)-isomer of
[18F]FEOBV. The concentrations of (2)- and (1)-
[18F]FEOBV enantiomers at 180 min in selected tissues
of the mouse are shown in Figure 4.
Rat biodistribution, dosimetry, and metabolism
As a prerequisite to using [18F]FEOBV in human
studies, rat whole body biodistribution studies (Table
III) were carried out to evaluate tracer disposition and
calculate expected radiation doses to man. [18F]FEOBV
radioactivity was eliminated from the body mainly
through the gastrointestinal tract. Nearly 50% of the
injected dose was found in the small bowel and contents
at 120 min. The estimated human internal radiation
dosimetry calculated from rat biodistribution using the
MIRD formalism is shown in Table IV. The upper large
intestine was estimated to receive the largest dose, 0.67
rad/mCi. This calculation allows up to a 10 mCi dose of
[18F]FEOBV to be administered to humans.
Modest bone uptake of radioactivity was seen with
[18F]FEOBV in rodents, which accumulated at a slow
rate following injection. Bone uptake was most likely
the result of metabolic defluorination of the tracer and
deposition of inorganic 18F2. The inactive (1) isomer of
[18F]FEOBV showed a similar level of bone uptake as
the active (2) form (Fig. 4).
Rodent brain tissue was analyzed for possible metabo-
lites of [18F]FEOBV at two times following injection.
The only radioactive species extractable from either
mouse or rat brain 30 and 90 min after administration
was unmetabolized FEOBV. The recovery of radioactiv-
ity from brain homogenates by the initial buffer/ethanol
extraction process was 90–97%, but large amounts of
lipid were present in the initial extract which interfered
with thin layer chromatography (TLC). The fatty sub-
stances were precipitated by addition of CH3CN and
the final extract was then analyzed by TLC without
difficulty. This defatting step reduced total recovery to
60–70%, but no selective precipitation of FEOBV me-
tabolites occurred with the fats. HPLC analysis of the
fat precipitate resolubilized in CH2Cl2 found only au-
thentic [18F]FEOBV present.
Radioactive metabolites of FEOBV appeared quickly
in rodent blood, were highly polar in nature, and easily
distinguishable from parent agent on TLC. They parti-
tioned strongly with the blood cell solids and resisted
extraction by the saline/ethanol combination, but the
methanol/trifluoroacetic acid mixture solubilized them.
When this extract was made basic with triethylamine
or KOH and then analyzed by normal phase TLC, all
radioactivity remained at the origin. Passage of the
basified extract through a short alumina column and
rinsing with methanol resulted in little trapping of
radioactivity on the column. This suggested that the
polar metabolite(s) was not inorganic [18F]fluoride ion.
Based on analyses from two rats, the percentage of
unmetabolized FEOBV in whole blood was ,80% at 5
min, 65–70% at 10 min, ,50% at 30 min, and less than
10% at 60 min. If the FEOBV blood metabolite profile in
rats holds true for primates, it may be possible to do
accurate blood activity metabolite corrections of the
input function in FEOBV-PET studies without the need
for chromatography, using a simple centrifugation of
whole blood diluted with a saline alcohol extractant. In
this case, the percentage of total blood activity in the
decanted supernatant would be equal to the amount of
unmetabolized FEOBV in the blood.
Toxicity
Unlabeled (2)-FEOBV was a strong neuromuscular
blocking agent in rodents. Mice given parenteral doses
quickly exhibited acute curare-like symptoms character-
istic of vesamicol intoxication (Rogers et al., 1989).
Intravenous doses as low as 30 µg/kg (2)-FEOBV were
lethal within 30 min. By contrast, (1)-FEOBV did not
kill mice at doses up to 4,000 µg/kg. Animals ventilated
mechanically survived at least five times the mean
lethal dose of (2)-FEOBV, suggesting that the primary
lethal event was respiratory paralysis. Survivors recov-
ered to apparent normalcy after 1–2 h, indicating
(2)-FEOBV was eliminated or otherwise detoxified at a
fairly rapid rate in rodents. No obvious behavioral or
neurological signs of longer term neurotoxicity were
seen in a small number of mice that were observed for 2
days following acute sublethal doses of (2)-FEOBV.
DISCUSSION
This work is a continuation of our earlier efforts to
develop radioiodinated and carbon-11 labeled benzove-
samicols [123I]IBVM and [11C]MABV as VAChT imaging
agents for studying cholinergic function in Alzheimer’s
disease (Jung et al., 1990; Kilbourn et al., 1990; Mulhol-
land et al., 1991a; Mulholland and Jung, 1992). These
agents have shown regional localization in vivo that
closely matches the distributions of cholinergic mark-
ers such as ChAT, high affinity choline uptake, and
acetylcholinesterase. The basic premise underlying the
applicability of benzovesamicol radiotracers in studies
of AD is that VAChT levels change in parallel fashion
and magnitude with other cholinergic marker proteins,
in particular ChAT, over the course of the disease. The
validity of this assumption has been debated, based on
results of some early studies showing mismatches
between [3H]vesamicol binding and ChAT in postmor-
tem AD brains (Kish et al., 1990; Ruberg et al., 1990),
but more recent studies using higher affinity VAChT
ligands (Efange et al., 1995b) or immunocytochemical
probes (Gilmor et al., 1997) suggest VAChT and ChAT
may in fact track closely together in AD and cholinergic
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Fig. 3. Autoradiographic distribution of (2)FEOBV in rat brain at
5 min (A) and 180 min (B) following bolus i.v. tracer injection. Each
time panel shows coronal sections at comparable rostrocaudal levels
from the head of the caudate (upper left) to the cerebellum and brain
stem (lower right). Tracer concentration is indicated by pseudocolor
transformation, according to the scale at the lower right of each panel,
with red and violet representing the highest and lowest levels,
respectively. Note the laminar cortical and selective subcortical reten-
tion is apparent even at 5 min. At 180 min, strong retention is present
in caudate (upper left section), basolateral amygdala (upper right),
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lesion models. It can be argued that vesamicol itself is
not a particularly good ligand for VAChT, since it also
binds other receptors (see below), and its affinity for
VAChT, (Kd , 11–36 nMratbrain, Marien et al., 1987); 1
nMtorpedoorgan, Rogers et al., 1993a) is much weaker than
analogs such as aminobenzovesamicol, ABV (Kd 5 6.5
pM, Rogers et al., 1993a). IBVM, MABV, and FEOBV
are very close analogs of ABV and have similar affini-
ties as ABV for the VAChT, as indicated by the similar
IC50 values for inhibition of 3H-MABV binding to rodent
cortical membranes (Jung et al., 1996; Mulholland,
unpublished).
Although it is very similar to [123I]IBVM and
[11C]MABV in VAChT binding properties in vivo,
[18F]FEOBV may possess advantages over the other
two agents as an imaging tracer for AD. When used
with PET, [18F]FEOBV has intrinsic quantification and
resolution advantages over [123I]IBVM/SPECT, which
could result in improved sensitivity and precision in
measuring cortical and hippocampal VAChT losses in
Fig. 4. Comparison of tissue uptakes of (2) and (1) isomers of [18F]FEOBV in the mouse at 180 min. Values represent mean 6SD of at least
three animals.
TABLE III. Whole body biodistribution of FEOBV in rats
5 min 15 min 30 min 120 min
Brain 1.47 6 0.11 1.58 6 0.20 1.15 6 0.12 0.87 6 0.13
Eyeballs 0.05 6 0.01 0.05 6 0.00 0.06 6 0.00 0.09 6 0.01
Heart 0.77 6 0.09 0.64 6 0.07 0.46 6 0.02 0.30 6 0.03
Lung 3.19 6 0.45 2.12 6 0.47 1.25 6 0.10 0.53 6 0.14
Liver 11.58 6 0.89 6.93 6 0.64 6.38 6 0.81 2.36 6 0.32
Pancreas 1.16 6 0.23 2.01 6 0.16 1.42 6 0.40 0.40 6 0.06
Spleen 0.80 6 0.18 0.73 6 0.11 0.53 6 0.06 0.18 6 0.04
Adrenal 0.18 6 0.06 0.06 6 0.05 0.06 6 0.02 0.03 6 0.01
Kidney 3.39 6 0.40 2.25 6 0.04 1.53 6 0.15 0.76 6 0.08
Stomach 1.11 6 0.13 1.34 6 0.12 1.23 6 0.26 0.54 6 0.11
Stomach contents 0.28 6 0.12 1.60 6 1.00 3.43 6 2.31 0.93 6 0.01
Small intestine 5.36 6 1.53 6.50 6 1.44 6.72 6 2.62 5.81 6 1.84
Small intestine contents 1.80 6 0.69 1.74 6 0.61 2.26 6 0.81 42.62 6 3.37
Caecum 0.51 6 0.10 0.45 6 0.08 0.42 6 0.10 0.48 6 0.05
Caecum contents 0.54 6 0.21 0.54 6 0.07 1.21 6 0.29 2.15 6 1.15
Large intestine 0.98 6 0.26 0.89 6 0.16 0.81 6 0.11 0.70 6 0.12
Large intestine contents 0.28 6 0.09 0.18 6 0.10 0.65 6 0.29 0.54 6 0.24
Ovary 0.28 6 0.01 0.14 6 0.01 0.11 6 0.01 0.05 6 0.01
Muscle* 0.32 6 0.14 0.30 6 0.04 0.27 6 0.05 0.18 6 0.02
Bone* 0.32 6 0.01 0.42 6 0.06 0.30 6 0.01 0.33 6 0.06
Urine 0.07 6 0.01 0.23 6 0.05 1.05 6 0.36 2.72 6 0.12
Blood* 0.22 6 0.03 0.22 6 0.03 0.026 6 0.03 0.28 6 0.02
Testes 0.71 6 0.03 0.75 6 0.02 0.98 6 0.03 0.82 6 0.12
Rest of carcass 68.2 6 2.2 67.7 6 1.8 68.9 6 3.6 37.67 6 3.1
Total recovery 101 6 2.5 98 6 1.9 98.4 6 3.0 95 6 4.0
Values are the mean percent injected dose per organ 6 SD of at least four animals at each time point, except where noted otherwise.
*Values expressed as percent injected dose per gram.
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AD (Kuhl et al., 1996). While [11C]MABV is also a PET
agent, [18F]FEOBV benefits from a longer halflife,
which enables late imaging at a point where near
steady-state binding levels are reached. Also, because
of differences in labeling chemistries between 18F and
11C, [18F]FEOBV can be obtained routinely at much
higher specific activity and lower dose masses than
[11C]MABV, thus improving the safety factor of
[18F]FEOBV in imaging studies.
A number of 18F-labeled benzovesamicols and vesami-
cols have been evaluated in the past as cholinergic
neuron imaging agents (Fig. 5). Our earlier work with
fluorobenzylamino-benzovesamicol (FBnABV) showed
the compound to have favorable cholinergic regional
brain distribution patterns in rodents and primates
following i.v. injection, but it suffered from relatively
low brain extraction, possibly due to the compound’s
high lipophilicity (Mulholland et al., 1991a,b). Two
[18F]fluoroacetyl derivatives of aminobenzovesamicol
called NEFA and FAA also have been reported (Ingvar
et al., 1993; Rogers et al., 1993b). FAA underwent rapid
metabolic loss of the label, but the more stable analog
NEFA showed a cholinergic pattern of regional brain
localization, and its binding was stereoselective to the
(2) isomer (Ingvar et al., 1993). In addition, two
fluorinated vesamicols have been studied. [18F]Fluoro-
methylvesamicol had very high brain extraction but did
not distribute in a pattern consistent with cholinergic
innervation (Rogers et al., 1993b). Another agent called
[18F]fluorobenzyltrozamicol (FBT) showed good brain
uptake and moderate cholinergic localization, with a
striatum/cerebellum ratio ,2 at 3 h in rodents as well
as primates (Efange et al., 1994; Mach et al., 1997).
Several vesamicol tracers have been reported to
interact with additional binding sites and neurotrans-
mitter systems besides the VAChT. Vesamicol itself
binds to s receptors and a ‘‘vesamicol-binding-protein,’’
independent of the VAChT (Hicks et al., 1991). Possibly
because of these secondary interactions, biodistribution
studies using tritiated (2)-vesamicol showed poor in
vivo localization in cholinergic brain areas (Jung et al.,
1990). Some vesamicol analogs (Efange et al., 1995a)
and (1)-benzovesamicol isomers (Jung et al., 1996) also
show high affinity for s receptors. Furthermore, dra-
matic increases in striatal tracer binding, up to 200% in
some cases, have been reported with certain analogs
following acute treatment with dopamine receptor an-
tagonists (Ingvar et al., 1993; Efange et al., 1994,
1995a, 1996). These other interactions could complicate
the interpretation of tracer data intended to assess
cholinergic presynaptic function.
We were unable to find evidence of strong binding
interactions in vivo of (2)-[18F]FEOBV with noncholin-
ergic receptors. Pharmacological pretreatment of mice
with large doses of the s ligand (1)-3-PPP, or E-2020, a
potent acetylcholinesterase inhibitor which also binds
s receptors, did not significantly alter the brain uptake
or regional localization of (2)-[18F]FEOBV (Table II).
Reductions in (2)-[18F]FEOBV total brain uptake and
blood levels occurred following haloperidol, a potent
antagonist of both D2 and s receptors, but it is likely
that blood flow changes caused by the near-stupefying
haloperidol doses given were responsible for the alter-
ations. In the 240-min haloperidol group, but not in the
earlier treatment groups, we did observe a striatal
%dose/g increase relative to controls that was signifi-
cant, and a nonsignificant trend (P . 0.05) toward
increased %dose/g levels for cortex, hippocampus
and cerebellum. However, the relative brain (2)-
[18F]FEOBV concentrations of the haloperidol groups,
expressed as an average of tissue-to-cerebellum ratios
from each animal, did not differ from controls (Table II).
This suggests, further, that haloperidol pretreatment
altered hemodynamic factors controlling tracer deliv-
ery to the brain, and did not modulate receptor availabil-
ity at the cellular level.
Our results argue that FEOBV is not interacting
competitively at sigma or D2-like receptor sites. In
vitro, we found haloperidol to be a very weak in-
hibitor (IC50 . 1 µM) of benzovesamicol [3H]MABV
binding to mouse striatal and cortical mem-
branes (Mulholland, unpublished findings). Further-
more, the equivocal effects of haloperidol on striatal
(2)-[18F]FEOBV binding we observed in mice indicate
that acute D2 receptor antagonism did not modulate
(increase) (2)-[18F]FEOBV binding to the VAChT
through a mechanism involving blockade of normal
dopamine inhibitory input onto cholinergic interneu-
rons in the striatum. There is evidence for an inhibitory
feedback circuit in the striatum and substantia nigra
involving dopamine D2, acetylcholine, and GABA neu-
rons (Lehmann and Langer, 1983), and several investi-
gators have suggested this interneuronal mechanism to
explain rapid, large increases they have observed in in
vivo striatal binding of certain vesamicol tracers follow-
ing acute D2 antagonist pretreatments (Efange et al.,
1994; Ingvar et al., 1993). We used haloperidol pretreat-
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ment doses 10–30 times higher than those investiga-
tors employed, but saw little effect on (2)-[18F]FEOBV
striatal localization. It should be pointed out we used
different species and intervals between haloperidol
pretreatment and tracer injection in our study. Further
investigation may be necessary to resolve whether our
differing results are due to altered experimental condi-
tions or basic differences in tracer properties between
FEOBV and other vesamicol agents.
(2)-[18F]FEOBV was excreted primarily through the
gastrointestinal tract. This excretion pattern results in
the large bowel being the body tissue which receives the
highest radioactive burden from intravenously adminis-
tered (2)-[18F]FEOBV, and limits the allowable dose to
10 mCi/year in adult humans, based on estimated
dosimetry calculations from rat data (Table IV). Gastro-
intestinal excretion is also the major disposition path-
way of [123I]IBVM in rats and humans (Kuhl et al.,
1994).
The absence of labeled brain metabolites of FEOBV
in rodents is a desirable feature of this agent. Assuming
this holds true in primates, it greatly simplifies the
tasks of estimating tracer brain transport and VAChT
binding site densities from PET studies with (2)-
[18F]FEOBV, since the total brain signal is contributed
by a single radiochemical entity. Furthermore, the
simple blood metabolism of (2)-[18F]FEOBV makes it
easy to do metabolite corrections of the plasma input
function for quantitative imaging studies. The resis-
tance of FEOBV to metabolic defluorination and bone
deposition is also noteworthy. In general, [18F]fluoroal-
kyl and [18F]fluoroalkylamino groups tend to be more
prone to loss of inorganic 18F2 than are [18F]fluoroaro-
matic groups. However FEOBV has a [18F]fluoroethoxy
group, and the presence of a vicinal oxygen atom in this
group appears to stabilize the 18F-label against defluori-
nation similar to the level of a [18F]fluoroaromatic
moiety. Relatively few [18F]fluoroethyl ethers have been
examined; however, in one case it was found this group
conferred the greatest metabolic stability in a series of
18F-labeled estrogens (French et al., 1993).
In vivo blocking studies using unlabeled vesamicol
analogs to prevent or displace (2)-[18F]FEOBV uptake
were not feasible because of their high toxicity. Previ-
ous in vivo [123I]IBVM blocking attempts using vesami-
col as the blocking treatment in rodents resulted in
death at a vesamicol dose that blocked about 50% of
control striatal IBVM uptake (Jung et al., 1990). How-
ever, in vitro ligand binding studies from this labora-
tory (Mulholland, unpublished findings) have found
5-substituted benzovesamicols to be very specific and
saturable in their binding to striatal, cortical, or hippo-
campal membranes, and this binding was inhibited by
nanomolar to subnanomolar concentrations of structur-
ally related benzovesamicols. For example, (2)-FEOBV
inhibited specific binding of the probe (2)-5-[3H]methyl-
aminobenzovesamicol ([3H]MABV, 80 Ci/mmol, 0.5 nM
incubation concentration) to mouse cortical membranes
with an apparent IC50 of 0.4 nM.
Biological stereospecificity is characteristic of other
benzovesamicols and vesamicol itself. Both the toxicity
and the cholinergic specificity were attributable almost
exclusively to the (2)-(2R,3R)-isomer of FEOBV. Mice
survived comparatively large doses of the (1)-isomer,
4,000 µg/kg i.v., that were 133 times greater than the
mean lethal dose of the (2)-isomer. The rodent biodistri-
butions of the two enantiomers were very different.
(1)-[18F]FEOBV activity was uniform throughout the
brain, and levels in all regions except cerebellum were
lower than uptake of the (2)-isomer. (1)-[18F]FEOBV
did not accumulate in peripheral tissues rich in cholin-
ergic terminals, such as atria, stomach, and pancreas,
in which (2)-[18F]FEOBV did localize (Fig. 4). Another
indication of the biological stereospecificity of FEOBV
was that the IC50 of (1)-FEOBV for inhibition of in vitro
(2)-[3H]MABV binding to cortical membranes was
Fig. 5. Various fluorine-18 vesamicol ana-
logs studied as cholinergic terminal imaging
agents.
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nearly three orders of magnitude higher than that of
the (2)-isomer. The clear relation between toxicity and
cholinergic localization in FEOBV enantiomers sug-
gests strongly that vesicular ACh uptake inhibition is
the direct cause of toxicity seen with (2)-FEOBV.
Toxic levels of vesamicol analogs cause respiratory
paralysis, probably through nondepolarizing blockade
of peripheral cholinergic neurotransmission. Nearly all
of the benzovesamicols we studied with high cholinergic
localization, including IBVM, MABV, and other analogs
(Mulholland et al., 1991b), share similar levels of
toxicity. Since binding and inhibition of VAChT at the
picomolar level (Rogers et al., 1993a) appears to be a
common mechanism underlying both the high choliner-
gic localization and toxicity of these agents, it is un-
likely these two properties can be separated in the
benzovesamicol class of cholinergic tracers.
High toxicity does not necessarily preclude useful-
ness as an imaging agent. Other very toxic compounds,
including thallium-201, carfentanil, (Dannals et al.,
1985), IBVM and epibatidine analogs (Ding et al., 1996;
Horti et al., 1997; Musachio et al., 1997; Villemagne et
al., 1997), have been used safely and/or are being
developed currently as human PET and SPECT imag-
ing agents. The very high specific activities attainable
routinely in fluorine-18-labeled agents, and the sensi-
tive HPLC techniques used universally in tracer purifi-
cation and analysis, make production of safe imaging
doses of (2)-[18F]FEOBV a reasonably straightforward
process. For example, a 10 mCi dose of (2)-[18F]FEOBV
with specific activity of 5 Ci/µmol, an easily achievable
value in our experience, contains only 2 nmol or 0.75 µg
of (2)-FEOBV drug. This low mass quantity is less than
1/1,000 of the estimated human toxic dose based on
mouse data, 1–2 mg (2.7–5.42 µmol, which incidentally
is more than the total amount of labeling precursor we
use per synthesis of (2)-[18F]FEOBV), and provides a
large margin of safety for human imaging studies.
Nevertheless, it is important to recognize the potential
risks of FEOBV and the vesamicol class in general, and
practice care in the production and quality control
standards for these tracers.
In conclusion, this work in rodents demonstrates
(2)-[18F]FEOBV to be a promising radiotracer for map-
ping cholinergic synapses in vivo. It has high brain
extraction, favorable metabolism, a strong cholinergic
pattern of localization which correlates highly with
brain choline acetyltransferase distribution, and lack of
demonstrable extra-cholinergic binding interactions.
Both the cholinergic tracer behavior and the pharmaco-
logical effects are stereospecific to the (2)-enantiomer.
Further work is needed to evaluate regional brain
kinetics of (2)-[18F]FEOBV in primates and develop
imaging and analysis protocols to extract information
from FEOBV-PET scans. It will then be possible to
determine the utility of this new agent for measuring
cholinergic synapse density and function in man using
PET.
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